Skip to main content
HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Pfizer's Centers for Therapeutic Innovation for NIH Researchers

Therapeutic Areas of Interest

Metastatic melanoma cells

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. (Credit: NIH National Cancer Institute Center for Cancer Research Photo/Julio C. Valencia)

For the most recent call for proposals, Pfizer was interested in research projects that fell within the following therapeutic areas:

  • Oncology: Targets/pathways that promote anti-tumor immune responses alone or in combination with checkpoint inhibitors; provide innate anti-tumor immune system activation; reduce or overcome tumor-induced immune suppression; or alter tumor microenvironment metabolism. Targets that promote directed tumor cell killing. Targets that address stromal heterogeneity, senescence, tumor plasticity, translational stress or protein stability. Novel cell-surface targets that enable mAb therapy.
  • Inflammation and Immunology: Targets/pathways that provide immune regulation but do not involve broad-based immunosuppression including adaptive and innate immunity, Th17 lymphocyte biology, regulatory cells and tolerance induction, or immune metablolism with a focus on rheumatoid arthritis, systemic lupus, erythematosus, inflammatory bowel disease, non-alcoholic steatohepatitis, atopic dermatitis, alopecia and vitiligo. Host-microbial interactions and microbiome are of interest with focus on epithelial barrier. 
  • Cardiovascular and Metabolic Diseases: Targets/pathways that decrease hepatic lipid content, inflammation and the development of liver fibrosis in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Novel approaches that reduce hyperinsulinemia and hyperglycemia. 
  • Neuroscience: Primary focus on Alzheimer's disease and Parkinson's disease. Targets/pathways with disease modifying and symptomatic potential. Chronic neuroinflammation mechanisms impacting the pathologies of Alzheimer's disease and Parkinson’s disease.
  • Rare Diseases: Targets/pathways representing novel therapeutic interventions for Hematologic (non-malignant) indications, including Haemophilia, sickle cell disease and beta-thalassemia; for skeletal and cardiac muscle diseases, including Duchenne/Becker muscular dystrophies; or for repeat expansion diseases, including Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal degeneration and myotonic dystrophy.

Learn more about each of these therapeutic areas of interest.